Hypertrophic Cardiomyopathy Mutations: Chinese Genetic Study
- A new study published in Precision Clinical Medicine highlights critically important genetic differences in hypertrophic cardiomyopathy (HCM) between Chinese and United Kingdom populations, emphasizing teh need for ethnicity-specific...
- Hypertrophic cardiomyopathy is a condition where the heart muscle becomes abnormally thick.
- Researchers analyzed sequencing data from 593 Chinese and 1,232 UK HCM patients, comparing them to control groups.The study, led by Wang, J., et al., found that Chinese patients...
Genetic Study Reveals Ethnic Differences in Hypertrophic Cardiomyopathy
Table of Contents
Published October 10, 2025, 23:48 PST
A new study published in Precision Clinical Medicine highlights critically important genetic differences in hypertrophic cardiomyopathy (HCM) between Chinese and United Kingdom populations, emphasizing teh need for ethnicity-specific genetic databases and diagnostic approaches.
Understanding Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy is a condition where the heart muscle becomes abnormally thick. This can lead to shortness of breath, chest pain, and, in severe cases, sudden cardiac death. HCM is often caused by genetic mutations, but the specific genes involved and the frequency of those mutations can vary significantly between different ethnic groups.
Key Findings: Chinese vs.UK HCM Patients
Researchers analyzed sequencing data from 593 Chinese and 1,232 UK HCM patients, comparing them to control groups.The study, led by Wang, J., et al., found that Chinese patients carried a substantially higher burden of rare genetic variants – 52.8% compared to 13.6% in the UK cohort. Though,the proportion of variants classified as pathogenic or likely pathogenic (P/LP) was similar between the two groups. This suggests that while Chinese patients have more rare variants they aren’t necessarily more likely to have variants with a clear disease-causing effect.
Two specific mutations where found to be unique to the Chinese cohort: MYBPC3 c.3624del, present in 2.9% of cases, and TNNT2 c.300C>G, found in 1.5% of cases. These findings indicate that these mutations may be especially relevant to HCM in individuals of Chinese ancestry. The study also revealed stronger associations with genes involved in thin filament and myosin light chain function in chinese patients, while non-truncating variants in the MYBPC3 gene were more common in the UK cohort.
Improving Variant Interpretation with genebe
A significant challenge in HCM genetic testing is the high number of variants of uncertain importance (VUS). These are genetic changes whose impact on heart function is unknown, leading to diagnostic uncertainty. The researchers employed the tool genebe to reclassify these VUS, successfully reducing their rate to 46.8%. This performance surpassed other variant classification tools, offering a clearer diagnostic picture for patients.
Implications for Clinical Management
The study’s findings underscore the critical importance of developing and utilizing ethnicity-specific genetic databases. Relying on databases primarily built from European populations can lead to misclassification of variants and inaccurate risk assessments in individuals from other ethnic backgrounds. Refined interpretation frameworks, tailored to specific populations, are essential for enhancing the clinical management of HCM and improving patient outcomes across diverse populations.